Literature DB >> 33735663

Has the excess risk of acute myocardial infarction in rheumatoid arthritis relative to the general population declined? A population study of trends over time.

Kiana Yazdani1, Hui Xie2, J Antonio Avina-Zubieta3, Yufei Zheng4, Michal Abrahamowicz5, Diane Lacaille6.   

Abstract

OBJECTIVE: To evaluate secular trend in ten-year risk of incident acute myocardial infarction (AMI) in incident rheumatoid arthritis (RA) relative to the general population.
METHODS: We conducted a retrospective study of population-based incident RA cohorts with RA incidence from 1997 to 2004 in British Columbia, Canada, with matched general population comparators, using administrative health data. RA and their matched cohorts were divided according to the year of RA incidence, defined according to the first RA visit of the case definition. Incident AMI was defined as the first event occurring within 10 years from RA incidence. Secular trend was assessed using delayed-entry Cox models with an interaction term between the year of RA onset and indicator of RA vs. general population. Linear, quadratic and spline functions of year of RA onset were compared to assess possibility of nonlinear trends. The model with the lowest AIC was selected to interpret the results. Sensitivity analyses were conducted to account for potential effect of unmeasured (e.g. smoking) or partially measured (e.g. obesity) confounders in administrative data, on the interaction term.
RESULTS: Overall, 23,237 RA and 46,474 general population controls experienced 1,133 and 1,606 incident AMIs, respectively. A linear Cox model was selected as the model best fitting the AMI events. Overall, RA patients were found to have a 21% higher risk of AMI than the matched general population controls [1.21 (1.10, 1.32); p < 0.001]. A significant linear decline in risk of AMI was observed in RA patients [0.94 (95% CI 0.91, 0.97) p = <0.0001], and in the general population [0.93 (0.91, 0.95); p = <0.0001]. The change in AMI risk over time did not differ in RA compared to the general population [p-value of interaction term=0.49]. Our results remained similar after adjusting for the potential effect of confounders on the interaction term, and no difference in the change in risk of AMI over time was observed between RA and the general population.
CONCLUSION: Our findings suggest a decline in 10-year risk of AMI in RA, and in the general population. The decline in the risk of AMI over time did not differ between RA and the general population, such that the excess risk of AMI in RA relative to the general population, has remained the same.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute myocardial infarction; Administrative data; Cardiovascular disease; Epidemiology; Rheumatoid arthritis; Temporal trends

Year:  2021        PMID: 33735663     DOI: 10.1016/j.semarthrit.2021.03.003

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  3 in total

1.  Risk Factors and Outcomes of Acute Myocardial Infarction in a Cohort of Antiphospholipid Syndrome.

Authors:  Yuzhou Gan; Yawei Zhao; Gongming Li; Hua Ye; Yunshan Zhou; Chang Hou; Lan Wang; Jianping Guo; Chun Li
Journal:  Front Cardiovasc Med       Date:  2022-07-05

2.  Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries.

Authors:  Benedicte Delcoigne; Lotta Ljung; Sella A Provan; Bente Glintborg; Merete Lund Hetland; Kathrine Lederballe Grøn; Ritva Peltomaa; Heikki Relas; Carl Turesson; Bjorn Gudbjornsson; Brigitte Michelsen; Johan Askling
Journal:  Ann Rheum Dis       Date:  2022-03-22       Impact factor: 27.973

3.  Effects of local cryotherapy on systemic endothelial activation, dysfunction, and vascular inflammation in adjuvant-induced arthritis (AIA) rats.

Authors:  H Martin; C Demougeot; C Peyronnel; P Totoson; V Petitcolin; F Bonnefoy; X Guillot; P Saas; F Verhoeven
Journal:  Arthritis Res Ther       Date:  2022-04-29       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.